White House announces the TrumpRx platform with a Pfizer pricing deal

President Trump announced on September 30, 2025 the first "most-favored-nation" (MFN) drug pricing agreement with a major manufacturer, Pfizer, and at the same time revealed TrumpRx, a government-run website where Americans could buy certain medicines directly from drugmakers at discounted cash prices ^[3][4]. Neither the Pfizer deal nor the site covered GLP-1 drugs, but the structure built that day became the template for the semaglutide and tirzepatide agreements announced five weeks later ^[2].

How the deal came together

The framework traces to an executive order Trump signed on May 12, 2025, titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which directed the Secretary of Health and Human Services to send MFN price targets to manufacturers and to set up direct-to-consumer purchasing programs for companies that sold at those prices ^[3]. On July 31, 2025, Trump sent letters to leading manufacturers spelling out the steps they needed to take to match the lowest price paid in other developed countries ^[2][3].

Under the September 30 agreement, Pfizer committed to give every state Medicaid program access to MFN prices on its products, to guarantee MFN pricing on all new medicines it brings to market, to repatriate increased foreign revenue, and to offer deep discounts when selling directly to American patients ^[3]. Pfizer also said it would invest $70 billion in US manufacturing and research and would be exempt from threatened pharmaceutical tariffs for three years ^[4].

Details about TrumpRx itself were thin. The administration named four Pfizer medicines — Eucrisa, Duavee, Zavzpret and Xeljanz — as available through the site, with a planned launch in "early 2026" ^[3]. The site will not sell or ship drugs. Customers search for a medicine, then get redirected to the manufacturer's own direct-to-consumer channel to buy it ^[4]. Pfizer said many of its drugs would see savings averaging 50% on TrumpRx compared with buying without insurance ^[4]. Discounts apply only to patients not using insurance ^[4].

That limit drew immediate scrutiny. Axios noted TrumpRx is unlikely to save much for the 92% of Americans who have health insurance, and cited Wall Street Journal reporting that most insured patients probably pay less through their plans than they would at TrumpRx cash prices ^[4]. Similar cash-price sites, including Mark Cuban's Cost Plus Drugs, already operate on the same model ^[4]. Cuban gave the program "a grade of B" based on what was known at the time ^[4]. One law-firm analysis said the biggest open question was whether a cash-price program would have any tangible effect on what insured patients pay ^[3].

Why it matters for patients

For people taking or considering GLP-1 medicines, the September 30 announcement matters mainly because of what followed. On November 6, 2025, the White House announced agreements with Novo Nordisk and Eli Lilly using the same structure: Ozempic and Wegovy prices falling from about $1,000 and $1,350 per month to $350 through TrumpRx, and Zepbound and orforglipron, if approved, falling from $1,086 to an average of $346 ^[1][2]. The initial dose of future oral GLP-1 drugs would be $150 per month through the site ^[2]. Medicare and state Medicaid prices for Ozempic, Wegovy, Mounjaro and Zepbound were set at $245, with Medicare covering Wegovy and Zepbound for obesity with related conditions for the first time and a $50 monthly co-pay for beneficiaries ^[1][2].

The same caveats from the Pfizer rollout carry over. TrumpRx prices are cash prices for people not billing insurance, and the site routes buyers to manufacturer channels rather than filling prescriptions itself ^[4]. Whether a given person pays less through TrumpRx or through their existing coverage depends on their plan, and the sources do not settle that comparison for GLP-1s.

What happens next

Officials said in October 2025 that they were still finalizing how the site would look and function, and the White House declined to comment on details ^[4]. TrumpRx.gov was not active at that time ^[4]. The White House has since posted a fact sheet dated February 5, 2026 titled "President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients" ^[2]. Since September 30, 2025, the administration says it has announced five deals with major manufacturers ^[2].